Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — FY2023 Earnings Presentation
19 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Mar 25, 2024
Slide 1: Earnings Presentation FY 2023
Earnings Presentation FY 2023 Jeddah | 25 March 2023
Slide 2: Business and Strategy Highlights
Business and Strategy Highlights
Slide 3: FY 2023 Performance Highlights
3 Business and Strategy Highlights FY 2023 Performance Highlights Revenue # of Brands Revenue crossed SAR 1 billion for the first 4Q 23 +9% YoY 11 new brands added; 2 new brands in Anti- FY 23 +20% YoY time ever driven by higher volumes, price Diabetes category increases and new product launches SAR
Slide 4: JP aims to become a significant healthcare contributor in MEA by 2026
4 Business and Strategy Highlights JP aims to become a significant healthcare contributor in MEA by 2026 To become a leading MEA organization by 2026 through consistently providing affordable, Vision high-quality healthcare solutions Foundations Operational Excellence Strategic Execution Leadership:
Slide 5: Strategic growth levers for 2024
5 Business and Strategy Highlights Strategic growth levers for 2024 Home Active Portfolio Facilities Business Market Markets Diversification Ramp-up Development Initiatives • Expand tender • Consolidate presence • Tap into broader • Accelerate • Enhance business participation and grow market share s
Slide 6: Facilities update
6 Business and Strategy Highlights Facilities update SAR 100bn+ of Total Addressable Market Jeddah Jeddah Egypt Algeria in Core Geographies By 2027 Main Facility Sterile Facility Facility Facility Iraq Kuwait Bahrain Egypt Qatar Kingdom of Saudi Arabia Operational Stability period Operational Operat
Slide 7: Driving revenue growth across key therapeutic areas and geographies
7 Business and Strategy Highlights Driving revenue growth across key therapeutic areas and geographies Revenue Movement by Therapeutic Area, YoY (SARmn) Revenue Movement by Country, YoY (SARmn) +20% +20% 133 31 14 10 1,101 917 (5) Split: +28% UAE 83% Private EGP Devaluation; +32% Bahrain 25 3 8 9 4
Slide 8: Portfolio diversification through faster expansion into new therapeutic areas
8 Business and Strategy Highlights Portfolio diversification through faster expansion into new therapeutic areas 2021 Revenue Contribution by Therapeutic Area (SARmn) 2023 Revenue Contribution by Therapeutic Area (SARmn) Pain & Inflammation Anti-diabetic 1% 26% C. Nervous System 5% Ophthalmology 2%
Slide 9: Pipeline overview
9 Business and Strategy Highlights Pipeline overview R&D Status for new Products Under SFDA review Ready for SFDA Submission Under Development Total 4 Ophthalmology 2 17 11 3 General Medicine 1 6 2 Revenue 2growth EBITDA Dermatology margin 3 3 2 Consumer Health 7 12 3 1 Gastrointestinal 2 8 5 2 Divi
Slide 10: Monthly revenue growth for top KSA pharma producers in the last two years
10 Business and Strategy Highlights Monthly revenue growth for top 5 KSA pharma producers in the last two years1 100% Peer 1 50% 9 negative months 0% -50% 200% Peer 2 100% 0% 5 negative months -100% 100% 50% 0% 1 negative month -50% 100% Peer 3 50% 8 negative months 0% -50% 200% Peer 4 100% 9 negati
Slide 11: Financial Highlights
Lajlé pgana Jamjoom Pharma Financial Highlights “<t—~
Slide 12: 4Q 2023 Key Highlights
12 Financial Highlights 4Q 2023 Key Highlights Revenue (SARmn) EBITDA (SARmn) +6% +19% 197 208 54 45 EBITDA Margin 19.2% 23.1% 28.0% 26.4% 26.0% 31.2% 26.9% 23.1% 26.9% 4Q 22 4Q 23 4Q 22 4Q 23 FCF (SARmn) Net Profit (SARmn) +51% +40% 45 44 30 32 FCF conversion 66.1% 81.8% 83.7% 84.4% 80.2% Net Profi
Slide 13: Cost efficiency gains preserve profitability
13 Financial Highlights Cost efficiency gains preserve profitability Cost of Revenue of Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +23% +11% Margin pressure stemming from market 25 11 386 and product mix changes 349 1 14 397 Includes IPO-related and 52 7 1 R&D/Sales reduced to 3% E
Slide 14: Jamjoom Pharma maintains its industry-leading margin profile
14 Financial Highlights Jamjoom Pharma maintains its industry-leading margin profile EBITDA Movement YoY (SARmn) EBITDA and Net Profit Margins (%) 33.8% +33% 31.3% 29.8% 29.2% 28.3% 184 EBITDA Margin 31.3% 25.7% EBITDA Margin 28.3% 11 344 26.6% (74) 21.4% (25) 23.2% 260 (11) 18.7% +20% +23% +10% +19
Slide 15: Reduction in receivables accelerates cash conversion
15 Financial Highlights Reduction in receivables accelerates cash conversion Cash Conversion Cycle (Days) ▪ Overall cash conversion cycle improved in 2023, reaching its lowest level in the past five years -12% ▪ Working capital amounted to SAR 498mn, up only 12% YoY, despite strong 321 revenue growt
Slide 16: Outlook and Guidance
Layla pagans Jamjoom Pharma Outlook and Guidance
Slide 17: Exceeding Financial Guidance Targets Across Key Metrics in 2023
17 Outlook and Guidance Exceeding Financial Guidance Targets Across Key Metrics in 2023 FY 2023 Guidance FY 2023 Actual Results Revenue growth 17-19% 20.1% EBITDA margin c.31% 31.3% CAPEX 4-6% 4.2% Interim dividend of SAR 1 per share Dividend (semi-annual) 50-60% payout ratio paid for 1H 2023 Final
Slide 18: 2024-26 Financial guidance
18 Outlook and Guidance 2024-26 Financial guidance Revenue growth EBITDA margin Revenue CAGR : 12-15% EBITDA margin: 30-31.5% Dividends CAPEX Dividend: 50-60% of net profit CAPEX: 4-6% of net revenue Payout: semi-annual Jamjoom Earnings Presentation - 25/03/24
Slide 19: Q&A Session
19 Q&A Session FY 2023 Earnings Presentation
Jamjoom Pharmaceuticals Factory — FY2023 Earnings Presentation on 6ix